| GOSSAMER BIO INC. |
| USA |
| Gesundheit |
| US38341P1021 / A2PCBS |
| 4GB (Frankfurt) / GOSS (NASDAQ) |
| FRA:4GB, ETR:4GB, 4GB:GR, NASDAQ:GOSS |
| - |
| https://www.gossamerbio.c.. |
|
Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in immunology, inflammation, and oncology. It centers its efforts on seralutinib, an investigational inhaled inhibito..
>Volltext.. |
| 33.7 Mio. EUR |
| 123.45 Mio. EUR |
| 48.15 Mio. EUR |
| -147.75 Mio. EUR |
| -156.4 Mio. EUR |
| -0.68 EUR |
| 175.94 Mio. EUR |
| 35.57 Mio. EUR |
| - |
| 1.76 |
| -58.26% |
| -229.67% |
| - |
| - |
| - |
| - |
| GOSSAMER BIO |
| 10.06.26 |
|